Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.68 |
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | VDR | P11473 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706676 | 1.00 | CDC25A (0.68) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL5583691 | 1.00 | CDC25A (0.68) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4738005 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4736748 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4736131 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4739286 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4736092 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4738483 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4735751 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR | |
| SCHEMBL4734430 | 0.89 | CDC25A (0.69) | CDC25APOLA1ST6GAL1USP2VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317251-B1 | TREATED SUBSTRATE WITH IMPROVED TRANSFER EFFICIENCY OF TOPICAL APPLICATION | KIMBERLY CLARK CO (US) | 2007-12-26 | — | — | EP | disclosed |
| US-6939553-B2 | Treated substrate with improved transfer efficiency of topical application | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1317251-A2 | TREATED SUBSTRATE WITH IMPROVED TRANSFER EFFICIENCY OF TOPICAL APPLICATION | Kimberly-Clark Worldwide, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020058056-A1 | Treated substrate with improved transfer efficiency of topical application | KIMBERLY-CLARK WORLDWIDE, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2002022104-A2 | TREATED SUBSTRATE WITH IMPROVED TRANSFER EFFICIENCY OF TOPICAL APPLICATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058056-A1 | Treated substrate with improved transfer efficiency of topical application | KRT18, COL14A1, CUTA | CDC25A 3656/4885POLA1 1828/4885ST6GAL1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.